Download - Psoriasis 2005
![Page 1: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/1.jpg)
1
Psoriasis
Mark Gill, PharmDProfessor of Clinical Pharmacy
U.S.C. School of PharmacySpring 2005
![Page 2: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/2.jpg)
2
Objectives Identify the pathogenic factors for
development of psoriasis List the clinical features of psoriasis Describe the progressive
management of the clinical features of psoriasis
List the adverse effects of psoriatic treatments
![Page 3: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/3.jpg)
3
Psoriasis
Chronic skin disorder; "itch" = psora
Incidence Other derm conditions
![Page 4: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/4.jpg)
4
Psoriasis T-cell mediated inflammatory dz
Epidermal hyperproliferation 2O to activation of immune system
Altered maturation of skin Inflammation Vascular changes
![Page 5: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/5.jpg)
5
![Page 6: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/6.jpg)
6
![Page 7: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/7.jpg)
7
![Page 8: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/8.jpg)
8
Background Epidemiology
Age Genetic Scandinavian/European descent
Risk Factors
![Page 9: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/9.jpg)
9
Psoriasis, an inherited disease
If you have psoriasis, what is the risk to:
Your unrelated neighbor? About 2%
Your sibling? 15-20% Your identical twin? 65-70% Your child? 25%
![Page 10: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/10.jpg)
10DERMIS
STRATUMBASALE
STRATUM SPINOSUM
STRATUM GRANULOSUM
STRATUM CORNEUM
Proliferation
Immaturity
Neutrophilaccumulation
DisorganizedNORMAL
PSORIASIS
![Page 11: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/11.jpg)
11
![Page 12: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/12.jpg)
12
Psoriasis: Associated Factors Genetic Factors:
- 30% of people with psoriasis have had psoriasis in family- Autosomal dominant inheritance
Nongenetic Factors:- Mechanical, ultraviolet, chemical injury- Infections: Strep, viral, HIV- Prescription Drugs, stress, endocrine, hormonal, obesity, alcohol, smoking
![Page 13: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/13.jpg)
13
Clinical Presentation Erythematous, raised patches with
silvery scales Symmetric Pruritic/ Painful Pitting Nails Arthritis in 10-20% of patients
![Page 14: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/14.jpg)
14
![Page 15: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/15.jpg)
15
Psoriasis: Clinical Presentation
Type Characteristics Plaque psoriasis Guttate psoriasis Erythrodermic psoriasis Pustular psoriasis Nail psoriasis Palmar/Plantar psoriasis Psoriatic arthritis Scalp psoriasis
Dry scaling patches (AKA common psoriasis) 75% Drop-like dots, occurs after strep or viral infection 12% Exfoliation of fine scales (total body “dandruff”), widespread, often accompanied by severe itching and pain 7% Pus-like blisters, noninfectious, fluid contains white blood cells 2% Seen on toenails and fingernails, starts as numerous pits, at times progresses to yellowing, crumbly, and thickened nail; nails may slough Erythema, thickening and peeling of the skin, blistering is often present. Can lead to disability. Inflammation, swelling, and joint destruction Plaque-type lesion
![Page 16: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/16.jpg)
16
Psoriatic Plaque
![Page 17: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/17.jpg)
17
Chronic Plaque Psoriasis
![Page 18: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/18.jpg)
18
Erythrodermic Psoriasis
![Page 19: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/19.jpg)
19
Nail changes
![Page 20: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/20.jpg)
20
Guttate Psoriasis
![Page 21: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/21.jpg)
21
Nail Changes In 78% of psoriatic patients Fingernails>Toenails Four changes
1. Onycholysis (= separation from nail bed)
2. Pitting*3. Subungual debris accumulation4. Color alterations*Pitting rules out a fungal infection
![Page 22: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/22.jpg)
22
![Page 23: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/23.jpg)
23
Psoriatic Arthritis In 10-20% of psoriasis patients Peripheral interphalangeal joints No elevated serum levels of
rheumatoid factors (as seen in rheumatoid arthritis, yet has all other features)
Often seen in patients with nail and scalp psoriasis
![Page 24: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/24.jpg)
24
OLA Photonumeric Guidelines(overall lesion assessment)
0 = none0 = none
5 = very severe5 = very severe4 = severe4 = severe3 = moderate3 = moderate
1 = minimal1 = minimal 2 = mild2 = mild
![Page 25: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/25.jpg)
25
![Page 26: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/26.jpg)
261 1 Leonardi, 2003; Leonardi, 2003; 2 2 Market Measures/Cozint LLP, June 2003.Market Measures/Cozint LLP, June 2003.
Othertherapies
54%
Topicalsonly
46%
The Majority of Moderate-Severe Psoriasis Patients Are Under-Treated
50% of patients with moderate or worse disease are currently untreated1
46% have topical therapy only Reason dermatologists
do not use more aggressive therapies2
Safety concerns Time consuming Cost
![Page 27: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/27.jpg)
27
Psoriasis: Treatment Lubrication Removal of scales Slow down lesion proliferation Pruritus management Prevent complications Lessen patient stress Season and climate
![Page 28: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/28.jpg)
28
Step 1
A n th ra lin C a lc ip o trie n e
C o a l T a r
T a za ro te ne In tra le s io na l S te ro id
T o p ica l S te ro id
C lim a to th e ra py M ois tu rize rs K era to lyt ic s
Step 2
P U V A P U V A +S te p 1 ag e n t
A c itre tin
Step 3
M e th o tre xa te C yc lo sp o rin eR o ta tio n a l:
1 2 -2 4 m o n thso f e a ch
s te p 3 ag e n t
Supplementary Tx
Step 4
Enbrel/Remicade/Amevive/Raptiva
![Page 29: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/29.jpg)
29
Treatment Annual Cost
Steroids 500-2,000
Dovonex 2,000-8,000
UVB 1,850
PUVA 3,300
Soriatane 6,150
Methotrexate 1,500-2,150
Cyclosporine 4,800
Biologics 10,000-15,000
![Page 30: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/30.jpg)
30
Emollients and Moisturizers
Moisturizes, lubricates and soothes dry and flaky skin.
Produces occlusive film to limit water evaporation from skin. Increased hydration allows stratum corneum to swell- scaling decreases, skin is more pliable.
Adverse Effect: contact dermatitis, folliculitis (rare)
![Page 31: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/31.jpg)
31
Keratolytics = “SKIN LIFTERS”
Helps remove scales and reduce hyperkeratosis
Salicylic Acid 2-6% Enhance absorption of other drugs AE: N/V, tinnitus, hyperventilation (rare
=salicylism)
![Page 32: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/32.jpg)
32
Tars Coal Tar – made from crude coal Decreases epidermal cell mitosis
and scale development Reduces sebum production Anti-inflammatory effects 5% coal tar concentration most
effective (1%-6%)
![Page 33: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/33.jpg)
33
Coal Tar
Problems with coal tar: Smell Sting Stain Sensitize
![Page 34: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/34.jpg)
34
Coal Tar Very useful in guttate psoriasis and for
scalp psoriasis as a shampoo Not recommended as 1st line tx:
Erythrodermic & Pustular Irritation may lead to Koebner’s phenomenon
Use only on lesions that are well separated, not too big
Phototoxic response sunburn may become erythematous
![Page 35: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/35.jpg)
35
Corticosteroids Reduce inflammation, itching and
scaling Anti-inflammatory effect
Decrease in vascular permeability, decreasing dermal edema and leukocyte penetration into skin
Antiproliferative effect Immunosuppressive effect
![Page 36: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/36.jpg)
36
CorticosteroidsLevel of Potency
Corticosteroid Commercial Products
Ultra-high Halobetasol propionateClobetasol propionateBetamethasone dipropionateDiflorasone diacetate
Ultravate crm/ointTemovate crm/ointDiprolene ointPsorcon oint
High HalcinonideAmcinonideBetamethasone dipropionateMometasone furoateDiflorasone diacetateFluocinonideDesoximetasone
Halog crmCylocort ointDiprolene AF crmElocon ointFlorone ointLidex crm,gel,ointTopicort crm,oint,gel
Mild to high HalcinonideTriamcinolone acetonideBetamethasone dipropionateFluocinonide
Halog oint,crm,solnAristocort A ointDiprosone crmLidex-E crm
![Page 37: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/37.jpg)
37
CorticosteroidsLevel of Potency
Corticosteroid Commercial Products
Mild Hydrocortisone valerateTriamcinolone acetonideFlurandrenolideMometasone furoateFluocinolone acetonide
WestcortKenalog crm and ointCordran ointElocon crmSynalar oint
Low to mild Hydrocortisone valerateTriamcinolone acetonideFlurandrenolideBetamethasone dipropionateHydrocortisone butyrateFlucolone acetonide
Westcort crmKenalog crm and ointCordran crmDiprosone lotionLocoid crmSynalar crm
Low Alclometasone dipropionateBetamethasone valerateFluocinolone acetonideHydrocortisone, dexamethasone, prednisolone, methylprednisolone
Aclovate crm and ointValisone lotionSynalar soln and crm
![Page 38: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/38.jpg)
38
Corticosteroids Ointments: helps hydrate; good for
dry, hyperkeratotic, scaly lesions Cream: for use on all areas, useful
for infected lesions Solutions: for scalp psoriasis, often
contain alcohols which can be painful with open lesions
![Page 39: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/39.jpg)
39
Corticosteroids Adverse Effects: (esp. with
occlusion) Systemic absorption Dermal atrophy Telangiectasis Ecchymoses Peri-orbital acne Poor wound healing Pyogenic infections
![Page 40: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/40.jpg)
40
Vitamin D3 Isolated from cod liver oil in 1936 Made in human skin through
reaction:7-dehydrocholesterol & UV light
Calcitriol’s properties in psoriasis:1. Increase cellular differentiation2. Inhibits cellular proliferation
![Page 41: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/41.jpg)
41
Vitamin D3 Adverse Effects:
Hypercalcemia Hypercalciuria Mild calcitriol intoxication: renal
stones Not for long term use, therefore
analogues were developed
![Page 42: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/42.jpg)
42
Vitamin D3 Analogue
Calcipotriene (Dovonex®) Indication = Moderate plaque psoriasis Reduces scaling and thickness of plaque,
but not the erythema; what would you use in combo?
Max weekly cumulative dose: 5mg= 100gm of 50 mcg/gm or 2 tubes
Applied BID x 8 weeks
![Page 43: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/43.jpg)
43
Vitamin D3 Analogues
Calcipotriene (Dovonex®) Not for pustular or erythrodermic psoriasis
due to increased systemic absorption AE: irritation, hypercalcemia (when applied
in large amounts) CI in pregnancy, lactation, children
![Page 44: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/44.jpg)
44
Retinoids Vitamin A derivatives
MOA:1.Normalization of abnormal keratinocyte differentiation
2.Reduction in keratinocyte proliferation
3.Reduction in inflammation
![Page 45: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/45.jpg)
45
Oral Retinoids Etretinate & Acitretin (Soriatane®) Second generation retinoids For pustular and erythrodermic psoriasis Etretinate withdrawn from US market-
1998 Acitretin= active metabolite of etretinate Reserved for treatment of severe forms of
psoriasis due to side effects.
![Page 46: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/46.jpg)
46
Soriatane : Dosage Usual dose: 25-50mg/day as
single dose Dosage form: 10mg, 25mg
capsules
![Page 47: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/47.jpg)
47
Soriatane : Precautions Avoid in severe liver and kidney dz Avoid in patients with h/o alcohol dz
ETOH = reverse metab to etretinate Teratogenic- CI in pregnancy
Contraception one month before treatment and at least 3 years after
Monitor: serum lipids, LFTs, serum creatinine (problematic as alternatives have similar limitations)
![Page 48: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/48.jpg)
48
Soriatane : Adverse Effects Peeling, drying skin Diffuse alopecia Nail changes Sticky, clammy skin Muscle pain Calcification of ligaments
![Page 49: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/49.jpg)
49
Hepatotoxicity 33% of patients had an elevation of AST (SGOT), ALT (SGPT) or LDHBlack Box Warning
Alopecia 50-75% of patients
Mucocutaneous50-75% skin peeling25-50% dry skin25-50% pruritus23% dry eyes
LipidMetabolism
66% increase in triglycerides33% increase in cholesterol40% reduction in HDL
Soriatane
![Page 50: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/50.jpg)
50
Topical Retinoids
Tazarotene (Tazorac®) Third generation retinoid Stable plaque psoriasis (up to 20%
of body surface area involvement) Severe facial psoriasis Water based emollient gel or
cream
![Page 51: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/51.jpg)
51
Tazarotene (Tazorac®)
Apply once daily x12 weeks AE: pruritus, burning, erythema ? More selective retinoid than
Soriatane resulting in fewer ADRs
Oral formulation pending at FDA
![Page 52: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/52.jpg)
52
Counseling points Apply a moisturizer to the skin before using the
Tazorac; it can dry out the skin.
Apply it once per day about 30 minutes before bedtime.
Rub about a pea-sized amount only into each lesion; it can irritate normal skin.
If it spreads to the unaffected skin, wash it off with water. Zinc oxide can protect the skin
Apply sunscreen
![Page 53: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/53.jpg)
53
Methotrexate For moderate-severe psoriasis non-
responsive to topical treatment MOA:
binds to DHFR which leads to reduction of tetrahydrofolate, which inhibits pyrimidine synthesis. Pyrimidine is needed for formation of DNA base pairs, therefore decrease in DNA replication esp rapidly dividing cells as in skin
Induces apoptosis of activated T cells
![Page 54: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/54.jpg)
54
FOLIC ACID
METHOTREXATE
![Page 55: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/55.jpg)
55
Response to Methotrexate Suppression of B cells and
macrophages Induces T-cell apoptosis Suppresses IL-1 and IL-8 production
by peripheral blood mononuclear cells
Reduces T cell production of interferon-gamma and TNF
![Page 56: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/56.jpg)
56
Methotrexate: Precautions Contraindicated:
Pregnancy, lactating mothers
Renal & liver problems Preexisting severe anemia,
leukopenia, thrombocytopenia
Alcoholics Active infectious disease
![Page 57: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/57.jpg)
57
Methotrexate: Dosage Initial: 2.5-5mg q12h x3 doses qweek Titrate up weekly by 2.5mg increments
[if blood counts (weekly then monthly) and LFTs (q4 month)allow] until symptoms respond
Injections: IM or SQ Max: 50mg/week, but some
75mg/week
![Page 58: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/58.jpg)
58
Methotrexate: Adverse Effects Headache, chills, fever, fatigue,
abdominal pain, nausea, vomiting, dizziness
Pruritus, alopecia, urticaria, ecchymosis, sunburn (phototoxicity)
Osteopathy- rare & at low doses Pulmonary fibrosis- CXR yearly Obtain liver biopsy after each 1.5gm Folate rx on days NOT taking MTX
![Page 59: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/59.jpg)
59
Cyclosporine
For psoriatic lesions resistant to other therapies
MOA: prevention of IL-2 transcription, prevention of primary T-cell activation and reduction of T cell cytokines.
![Page 60: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/60.jpg)
60
Cyclosporine: Dosage Oral Cyclosporine Microemulsion:
Neoral Capsules, solution Initial: 2.5 mg/kg/day split BID x4 wks May increase dose at 2 week intervals
of ~0.5 mg/kg/day increments Max: 5 mg/kg/day Relapse:
6 weeks (50%)-16 weeks (75%)
![Page 61: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/61.jpg)
61
Cyclosporine:Adverse Effects
Headaches, paresthesias, flu-like symptoms, abdominal pain, nausea.
Hypertension Nephrotoxicity:acute blood flow; chronic
form dose and duration Neurotoxicity Hepatoxicity Hyperglycemia Should be used as short term therapy (<1
year) to avoid further adverse effects (gingival hyperplasia, hyperlipidemia, hirsutism, etc).
![Page 62: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/62.jpg)
62
Phototherapy Used over 100 years for moderate-
severe psoriasis UVA (315-400 nm), UVB (290-315
nm)
313 nm = most effective wavelength for psoriasis
![Page 63: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/63.jpg)
63
Phototherapy Ultraviolet B
Relatively non-toxic Can be used as a single-agent Usually combined with lubricants Ingram’s regimen (Anthralin) Goeckerman’s regimen (Tar)
![Page 64: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/64.jpg)
64
Phototherapy
![Page 65: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/65.jpg)
65
Phototherapy
![Page 66: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/66.jpg)
66
Phototherapy
![Page 67: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/67.jpg)
67
Phototherapy
![Page 68: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/68.jpg)
68
PUVA PUVA= Psoralen + Ultraviolet A Theories of MOA:
1. Psoralen intercalates into DNA, inhibiting DNA replication and thus, inhibiting epidermal cell hyperproliferation
2. Free radical formation damages cell membrane, cytoplasmic contents and nucleus of epidermal cells…inhibiting growth of cells.
3. Increased apoptosis of activated T-cells
![Page 69: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/69.jpg)
69
Oral PUVA
Psoralen = “P” in PUVA = a photosensitizer
Methoxsalen (Oxsoralen-Ultra, 8-MOP) 10 mg capsules Given 2 hours before UVA irradiation Symptomatic control of severe,
recalcitrant disabling psoriasis, not responsive to other therapy after biopsy confirmed diagnosis
![Page 70: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/70.jpg)
70
PUVA Phototoxicity
Related to quantity of psoralen and amount of UVA applied
Reaction peaks 48-72hrs after treatment Erythema, blistering, edema
Administer 2-4x/ week Tanning occurs, so gradually increase
dose of UVA ~20 sessions over 4-8 weeks clears
lesions
![Page 71: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/71.jpg)
71
Oral PUVA: Adverse Effects Constipation, diarrhea, nausea,
vomiting, pruritus, delayed-onset erythema
Oral psoralens distribute to entire body and eyes: protect eyes and skin from sunlight 6 hours after treatment
Long-term: premature aging, cataracts, skin cancer (rare)
![Page 72: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/72.jpg)
72
First Generation Biologicals Infliximab & Etanercept:
immunomodulators used initially for rheumatoid
arthritis; work against TNF-alpha
![Page 73: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/73.jpg)
73(soluble TNF receptor)
![Page 74: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/74.jpg)
74
TNF Inhibitors Both Remicade and Enbrel are quite
effective (>75% of psoriatics respond) even if only skin is affected
Enbrel SQ once* or twice weekly; Remicade IV0, 2 and 6 weeks
Concerns: exacerbate MS and TB, induce SLE and CHF, palliative not curative
![Page 75: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/75.jpg)
75
New Therapies Alefacept (Amevive)
Inhibits CD45RO+ memory effector T lymphocytes, by binding to their CD2 receptor also leads to apoptosis
Administered IV or IM qweek x12 wks
AE: dizziness, chill, nausea, cough
![Page 76: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/76.jpg)
76Amevive binds to activated T cells
No binding
![Page 77: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/77.jpg)
77
Psoriasis Area Severity Index (PASI) and CD4+ T-cell count
Amevive response
![Page 78: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/78.jpg)
78
The recommended dose of AMEVIVE® is 7.5 mg given once weekly as an IV bolus or 15 mg given once weekly IM injection (F=63%).
The recommended regimen is a course of 12 weekly injections (t1/2 = 270 hrs)
Retreatment with an additional 12-week course may be initiated provided that CD4+ T lymphocyte counts are within the normal range, and a minimum of a 12-week interval has passed since the previous course of treatment. Data on retreatment beyond two cycles are limited
No flares reported
![Page 79: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/79.jpg)
79
Amevive Cautions May induce malignancies; avoid in
patients with systemic malignancy May lead to infections Has been associated with liver
damage esp in ETOH abuse
![Page 80: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/80.jpg)
80
Raptiva
Efalizumab (Raptiva) is a humanized monoclonal antibody of CD11a that works by blocking T-cell binding and trafficking into the dermis and epidermis.
FDA approved October 29, 2003
![Page 81: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/81.jpg)
81
![Page 82: Psoriasis 2005](https://reader035.vdocument.in/reader035/viewer/2022082209/55cf8f78550346703b9cb2e0/html5/thumbnails/82.jpg)
82
Raptiva Indicated for adults with mod/severe
chronic psoriasis SQ admin, priming dose 0.7 mg/kg (to
lessen 1st dose reax of HA, fever, N&V) then 1 mg/kg q wk.
ADR: infxns, malignancy, platelets, worsen psoriasis, avoid immunizations
Use beyond one year unknown, re-start of Tx often poor response=suppressive not remittive like Amevive